Neonc Technologies Holdings (NTHI) EBT Margin (2024 - 2025)
Neonc Technologies Holdings (NTHI) posted quarterly EBT Margin of 80415.27% for Q1 2025, down 7358044.0% year-over-year from N/an in Q1 2024, and down 662.99% quarter-over-quarter from 10539.42% in Q4 2024.
Neonc Technologies Holdings (NTHI) EBT Margin (2024 - 2025) Analysis & Trends
Neonc Technologies Holdings (NTHI) has reported EBT Margin for 2 consecutive years, with 80415.27% the latest figure, recorded in Q1 2025.
- In Q1 2025, EBT Margin fell 7358044.0% year-over-year to 80415.27%; the TTM figure through Dec 2025 stood at 151787.31% (down 14261439.0% YoY), while the FY2025 annual figure was 205554.9%, down 18341811.0% from the prior year.
- EBT Margin retreated to 80415.27% in Q1 2025 per NTHI's latest filing, from 10539.42% in the prior quarter.
- Across five years, EBT Margin topped out at 1910.8% in Q2 2024 and bottomed at 80415.27% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Neonc Technologies Holdings | 116.41 Mn | 116.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -80,415.27% |
| Dec 31, 2024 | -10,539.43% |
| Jun 30, 2024 | -1,910.80% |
| Mar 31, 2024 | -6,834.83% |